L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells by Doberstein, Kai et al.
Carcinogenesis vol.32 no.3 pp.262–270, 2011
doi:10.1093/carcin/bgq249
Advance Access publication November 19, 2010
L1-CAM expression in ccRCC correlates with shorter patients survival times and
confers chemoresistance in renal cell carcinoma cells
Kai Doberstein, Anja Wieland1, Sophia B. Boyoung Lee,
Roman A. Alexander Blaheta2, Steffen Wedel2, Holger
Moch3, Peter Schraml3, Josef Pfeilschifter, Glen
Kristiansen3 and Paul Gutwein
Pharmacology, pharmazentrum frankfurt/ZAFES, University Hospital Goethe
University Frankfurt, D 60590 Frankfurt am Main, Germany, 1Institute of
Reconstructive Neurobiology, Life & Brain Center, University of Bonn and
Hertie Foundation, D 53127 Bonn, Germany, 2Department of Urology and
Pediatric Urology, Goethe University Frankfurt, D 60590 Frankfurt am Main,
Germany and 3Institute of Surgical Pathology, University Hospital Zurich,
University of Zurich, 8091 Zurich, Switzerland
To whom correspondence should be addressed. pharmazentrum frankfurt,
Klinikum der Johann Wolfgang Goethe-Universita¨t Frankfurt, Theodor-
Stern-Kai 7, D-60590 Frankfurt am Main, Germany. Tel: þ49 69 6301 4920;
Fax: þ49 69 6301 79 42;
Email: p.gutwein@med.uni-frankfurt.de
Conflicting data exist about the expression of L1 cell adhesion
molecule (L1-CAM) in clear cell renal cell carcinoma (ccRCC).
To determine the clinical usefulness of L1-CAM as a therapeutic
or prognostic marker molecule in renal cancer patients, we ana-
lyzed its expression on a cohort of 282 renal cell carcinoma (RCC)
patients. L1-CAM expression was found in 49.5% of 282 renal
cancer tissues. Importantly, L1-CAM expression in patients with
ccRCC was associated with significantly shorter patient survival
time. We further present evidence that L1-CAM was involved in
the resistance against therapeutic reagents like rapamycin,
sunitinib and cisplatin. The downregulation of L1-CAM expres-
sion decreased renal cancer cell proliferation and reduced the
expression of cyclin D1. In addition, we found out that Von Hippel-
Lindau (VHL) deficiency was accompanied by a downregulation
of the transcription factor PAX8 and L1-CAM. In normal renal
tissue, PAX8 and L1-CAM were co-expressed in collecting duct
cells. Importantly, the downregulation of PAX8 by small interfer-
ing RNA increased the expression of L1-CAM and concomitantly
induced the migration of renal cancer cells. Furthermore, we
observed in 65.3% of 282 RCC patients a downregulation of
PAX8 expression. With chromatin immunoprecipitation analysis,
we additionally demonstrate that PAX8 can bind to the promoter
of L1-CAM and we further observed that the downregulation of
PAX8 was accompanied by increased L1-CAM expression in
a high fraction of ccRCC patients. In summary, we show that
VHL and PAX8 are involved in the regulation of L1-CAM in renal
cancer and L1-CAM represents an important therapeutic and
prognostic marker protein for the treatment of ccRCC.
Introduction
Renal cell carcinoma (RCC) accounts for 2–3% of all malignant dis-
eases in adults (1). The incidence of RCC is rising worldwide and is
209 000 cases/year and 102 000 deaths/year (2). Although the
5 years survival is 60% overall for kidney cancer, it drops to 10% in
patients with metastatic disease (3). Therefore, alternative approaches
are urgently required to prolong patient survival since very few effec-
tive therapeutic regimens are available. In this context, L1 cell adhe-
sion molecule (L1-CAM) has been shown to be an interesting target
protein for the treatment of different types of cancer (4). L1-CAM
belongs to the immunoglobulin superfamily of cell adhesion mole-
cules and it consists of six immunoglobulin-like domains, five fibro-
nectin type 3 repeats, a single transmembrane region and a short
cytoplasmic tail (5). In addition to the transmembrane form of L1-
CAM, a soluble form of L1-CAM can be released from the cell
surface or in released vesicles through the activity of ADAM10 (6).
So far, the data on L1-CAM expression in clear cell renal cell car-
cinoma (ccRCC) are contradictory. Allory et al. (7) has reported that
47% of ccRCC analyzed were positive for L1-CAM, whereas Huszar
et al. (8) showed that ccRCC did not express L1-CAM. Intriguingly, it
has been reported that L1-CAM expression in ccRCC correlated with
metastasis (7). L1-CAM is often not expressed in normal tissue, but
induced expression can be found in melanoma, ovarian and breast
cancer (9). The presence of L1-CAM in cancer tissue is commonly
correlated with a poor prognosis and more advanced stages of the
disease; therefore, it is of great importance to identify factors, which
regulate L1-CAM in cancer cells. In the nervous system, it has been
shown that the transcription factor PAX6 is able to activate L1-CAM
expression (10). In the kidney, PAX2 and PAX8 are the best-charac-
terized family members and it is known that both factors play crucial
roles in the developing kidney by specifying the nephric lineage (11).
In addition to fetal tissue, PAX2 overexpression has been found in
several human tumors like ovarian, breast and ccRCC (12). Recently,
hypoxia and the loss of Von Hippel-Lindau (VHL) function has been
linked to PAX2 upregulation (13). The best-described function of
VHL as a transcriptional regulator is its ability of targeting the a
subunits of hypoxia inducible factor for ubiquitin-mediated proteol-
ysis. It is well-known that the loss of VHL in ccRCC, which is a com-
mon event, provokes cell invasion, angiogenesis and tumor cell
survival (14). In this study, we analyzed the expression of L1-CAM
and PAX8 in 282 clinically characterized RCC cases and correlated
their expression with patient’s survival. We provide evidence that
VHL is involved in the regulation of L1-CAM in RCC. Furthermore,
knockdown of L1-CAM abrogated the chemoresistance of renal can-
cer cells against cisplatin, which endorses that targeting L1-CAM
represents a promising therapeutic option in the treatment of ccRCC.
Materials and methods
Antibodies
The VHL antibody was ordered from Santa Cruz Biotechnology, Heidelberg,
Germany. The monoclonal antibodies L1 11A and L1 14.10 were a kind gift
from Prof. Peter Altevogt (German Cancer Center, Heidelberg, Germany). The
polyclonal PAX8 antibody was a kind gift from Prof. Roberto Di Lauro (Sta-
zione Zoologica Anton Dohrn, Napoli, Italy). For western blot analysis, the
Hemagglutinin tag antibody (Abcam plc, Cambridge, UK), Histone deacety-
lase antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and b-actin anti-
body (Sigma–Aldrich, St Louis, MO) were used.
Cell culture
The renal carcinoma cell lines A-498 and 786-O were obtained from Prof.
Wilhelm Krek (Institute of Cell Biology Zu¨rich, Switzerland) and are de-
scribed elsewhere (15). The renal cancer cell line Fo¨hn was a kind gift from
Prof. Altevogt (German Cancer Research Center, Heidelberg, Germany). Cells
were grown under normoxic (21% O2) or hypoxic (1% O2) in a Napco 7001
incubator (Precision Scientific, Chennai, India).
Membrane isolation, protein extraction and western blot analysis
Membrane fractions were isolated by incubating the cells for 10 min in hypol-
ysis buffer [10 mM Tris–HCl pH 8.0, 0.1 mM dithiothreitol, Protease Inhibitor
complete (Roche Diagnostic, Penzberg, Germany)] at 4C. Cell suspension
was homogenized in a glass homogenizer and membrane proteins were centri-
fuged at 1000g at 4C followed by a high-speed centrifugation at 100 000g.
Protein lysates of renal cancer cells and western blot analysis were performed
as described in ref. 16.
Abbreviations: ChIP, chromatin immunoprecipitation; ccRCC, clear cell renal
cell carcinoma; L1-CAM, L1 cell adhesion molecule; mRNA, messenger
RNA; PCR, polymerase chain reaction; RCC, renal cell carcinoma; siRNA,
small interfering; TMA, tissue microarray; VHL, Von Hippel-Lindau; WT,
wild-type.
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Nucleus isolation
Cells (1 107 cells) grown on a 10 cm dish were trypsinized and washed twice
with phosphate-buffered saline and nuclear proteins were isolated as described
in ref. 16.
Fluorescence microscopy
Cells were grown on coverslips and fixed with 4% paraformaldehyde/
phosphate-buffered saline. Immunofluorescence stainings of cells or renal tis-
sue sections were performed as described in ref. 17.
Complementary DNA synthesis and polymerase chain reaction analysis
RNA from cultured cells was isolated using the RNA Easy Kit according to the
manufacturer’s protocol (Qiagen, Hilden, Germany). Equal amounts of total
cellular RNA (1 lg) were reverse transcribed with random primer by the use of
M-MuLV Reverse Transcriptase (Fermentas, St Leon-Rot, Germany). Tran-
scribed complementary DNAs were used for polymerase chain reaction (PCR)
with specific primers for human L1-CAM (5#-GACTACGAGATCCACTTGT-
TTAAGGA-3# and 5#-CTCACAAAGCCGATGAACCA-3#), PAX8 (5#-TCA-
ACCTCCCTATGGACAGC-3# and 5#-GCCTCGCTGTAGGAGGAGTATGTT-
3#), PAX2 (5#-CCCAGCGTCTCTTCCATCA-3# and 5#-CCACACCACTC-
TGGGAATCT-3#) and b-actin (5#-GGACTTCGAGCAAGAGATGG-3# and
5#-AGCACTGTGTTGGCGTACAG-3#). PCR products were amplified using
Taq DNA polymerase (NatuTec, Frankfurt, Germany) and subjected to electro-
phoresis through 2% agarose gels and ethidium bromide staining.
Real-time PCR
Real-time PCR was performed as described in the protocol from the Absolute
Blue QPCR SYBR Green Low ROX Kit (Thermo Scientific, Hilden, Germany).
The same primers that were used for the PCR were also used for the real-time
PCR. The C(T) values of L1-CAM and PAX8 messenger RNA (mRNA) level
were normalized to the C(T) values of b-actin mRNA within the same sample.
si RNA transfection
Small interfering RNA (siRNA) duplexes were used for the downregulation of
PAX8 expression (PAX8-siRNA: 5#-UCUUUAUUUAUUACAUGAA-3#) and
L1-CAM expression (L1-CAM-siRNA 5#-AGGGAUGGUGUCCACUU-
CAAATT-3#). As a negative control, unspecific scrambled siRNA duplexes
(5#-AGGUAGUGUAAUCGCCUUGTT-3#) were applied. Twenty-four hours
before transfection, 0.5 105 cells were seeded in six-well plates. Transfection
of siRNA was carried out using Oligofectamine (Invitrogen, Karlsruhe,
Germany) and 10 nM siRNA duplex per well as described in ref. 18.
Tissue microarray construction
We constructed a tissue microarray (TMA) from RCC diagnosed at the Institute of
Surgical Pathology, Universita¨tsspital Zurich, between 1993 and 2003, as re-
cently described (19,20). Two hundred and eighty-two renal carcinomas were
represented on the TMA. Staging met the Union for International Cancer Control
2002 criteria. Histological classification and grading was performed according to
the World Health Organization. The median patient age was 63 years (range: 29–
88 years). Of 184 patients were men, 98 women. The majority of the carcinomas
were of clear cell type (n5 230; 81.6%). The remaining RCC were of papillary
(n5 42; 14.9%) and chromophobe (n5 10; 3.6%) types. The tumor-status (pT)
for these cases was as follows: pT1—121 (42.9%), pT2—36 (12.8%) and
pT3—125 (44.3%).
The Fuhrman grades were G1 in 3 (1.1%), G2 in 94 (33.3%), G3 in 120 (42.6%)
and G4 in 65 (23.0%) cases, respectively. Disease-specific death occurred in 106
patients (37.6%) after a median survival time of 18 months (range 0–123). Data
on the Eastern Cooperative Oncology Group performance status were not avail-
able. In the TMA, each tumor was represented by one tissue core (0.6 mm).
ccRCC test TMA
A test TMA consisting of seven ccRCCs with wild-type (WT) VHL and eight
with frameshift mutations in VHL was generated as described in ref. 13.
TMA immunohistochemistry
The TMA blocks were freshly cut (3 lm) and mounted on superfrost slides
(Menzel Gla¨ser, Braunschweig, Germany). Immunohistochemistry was con-
ducted with the Ventana Benchmark automated staining system (Ventana Medical
System, Tucson, AZ) using Ventana reagents for the entire procedure. The L1-
CAM and PAX8 antibodies were used at a concentration of 1:100. For detection,
we used UltraVIEWTM DAB detection kit using the benchmarks CC1m-heat
induced epitope retrieval. Slides were counterstained with hematoxylin, dehy-
drated and mounted.
Evaluation of TMA immunohistochemistry
The immunohistochemistry was evaluated by a single GU pathologist (G.K.) to
minimize intraobserver variability. Intensity of immunoreactivity was semi-
quantively scored as negative, weakly, moderately or strongly positive. A panel
of representative figures was compiled before the systematic evaluation of the
tumor cohort was used as a reference, which layed next to the microscope for
continuous comparison.
Statistical analysis of immunohistochemistry data
The data were compiled with the software package SPSS, version 15.0 (SPSS
Software, Mu¨nchen, Germany). Spearman’s Rho was used to assess the statis-
tical significance of the correlation between molecular and clinicopathological
parameters. Univariate survival analysis was performed according to Kaplan–
Meier, and differences in survival curves were assessed with the log rank test.
Additionally, univariate Cox models were calculated. Multivariate survival
analysis was performed on all the parameters that were found to be significant
on univariate analysis using the Cox regression model. P , 0.05 was consid-
ered statistically significant.
Nucleofection
Cells were nucleofected using materials supplied in the Amaxa Cell Line
Optimization Nucleofector KitTM (Lonza, Cologne, Germany). Fo¨hn cells
(2  106) were suspended in Cell Line Nucleofector Solution V (added with
supplement) and mixed with 5 lg PAX8–pcDNA 3.1 plasmid DNA (kind gift
of Prof. Vassart, Brussels, Belgium). Control cells were transfected with
empty pcDNA 3.1 plasmid DNA. The nucleofected cells were transferred to
a six-well plates containing fresh, prewarmed RPMI with 10% fetal bovine
serum (0.7  106 cells per well) and maintained at 37C.
Cell cycle analysis
Cells were seeded in six-well plates and transfected with siRNA as described
before. Forty-eight hours after siRNA transfection, cells were left untreated or
treated with 40 lM cisplatin (CDDP) for 24 h. Afterward, the cells were trypsi-
nized, washed in phosphate-buffered saline and cell cycles analysis was performed
as described in ref. 16. Data are presented by means ± standard deviations.
Statistical and significant differences were determined using the Student’s t-test.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP)-IT Express kit (Active Motif, Rix-
ensart, Belgium) was used to perform the ChIP assay. Four dishes (10 cm) of
A498 renal cancer cells with 1  106 cells per dish were treated with 1%
formaldehyde, followed by glycine stop solution. Afterward, cells were har-
vested, centrifuged and resuspended in lysis buffer. After 30 min of lysis and
homogenization in a douncer, nuclei were collected and resuspended in shear-
ing buffer. Enzymatic shearing was performed for 10 min to digest DNA in
DNA fragments ranging in size from 200 to 500 bp. Afterward, 10 ll of the
sheared chromatin was used as input control. The immunoprecipitation was
performed overnight at 4C using a head to head rotator. The incubation
mixture containing 50 ll sheared chromatin, protein G magnetic beads and 3
lg PAX8 antibody (Proteintech Europe, Manchester, UK). After washing and
elution, the samples were reverse cross-linked and treated with ribonuclease A
and proteinase K. The DNA and the sheared chromatin input was directly used
for PCR analysis. The primer pair 5#-GCAGCCAGCTCGCCGGCTCC-3# and
5#-CAGCCCTGCACAGGATCGAG-3# was designed to amplify a 129 bp
product of the human L1-CAM promoter (GenBank-accession U52112).
Cell migration assay
Cell migration was measured as described (21). Each experiment was per-
formed in triplicates and repeated at least three times. Data are presented by
means ± standard deviations. Statistical and significant differences were de-
termined using the Student’s t-test.
Results
L1-CAM expression in ccRCC tissue correlates with shorter patients
survival
Contradictory data exist about the expression of L1-CAM in
ccRCC (7,8). Therefore, we analyzed the expression of L1-CAM
by immunohistochemistry on a TMA with 282 renal tumor samples.
For the immunohistochemistry analysis, we used a monoclonal an-
tibody against L1-CAM (L1 14.10), which was also used in the
study of Huszar et al. (8). Representative stainings of L1-CAM
expression in normal kidney and tumor samples (negative, weak
and strong expression) are shown in Figure 1A. The obtained results
are summarized in a diagram (Figure 1B). Interestingly, from 282
stained renal tumors, 49.5% expressed L1-CAM. To further inves-
tigate the clinical usefulness of L1-CAM expression in RCC
L1-CAM, PAX8, renal cancer and VHL
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Fig. 1. Expression of L1-CAM in normal kidney and renal cancer on a TMA. (A) Immunohistochemistry images showing the expression of L1-CAM in normal
kidney and a representative image of negative, weak positive and strong positive L1-CAM staining in renal cancer patients (RCC). Scale bars represent 50 lm.
(B) Pie charts demonstrate the relative proportion of negative (blue), weak positive (yellow), moderate positive (red) and strong (maroon) L1-CAM-positive cases
of RCC. (C) Kaplan–Meier survival analysis of the relationship between the expression of L1-CAM and the length of patient survival. Dotted line indicate patients
with low levels of L1-CAM expression (n5 222), bold line represents patients with high levels of L1-CAM (n5 41). (D) L1-CAM expression in a TMA of eight
ccRCC patients (1–8) with mutated VHL status. Scale bars represent 50 lm. (E) Immunohistochemical analysis revealed that three of seven patients with VHL WT
ccRCC showed strong L1-CAM expression. Scale bars represent 50 lm. (F) Immunohistochemical staining with isotype-specific antibodies (anti-mouse igG) on
human kidney sections was performed to determine the specificity of the monoclonal L1-CAM antibody (L1.14.10). (G) Seventy-two hours after the transfection
of L1-CAM-specific siRNA, lysates of A498 VHL cells were prepared and western blot analysis with a monoclonal antibody against L1-CAM (L1 14.10) was
performed. b-Actin was used to confirm equal protein loading.
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patients, we compared the L1-CAM expression with the survival
times of the analyzed patients. Postoperative follow-up data (me-
dian 40 months, range 1–140 months) were available for 264 pa-
tients. Importantly, L1-CAM expression in RCC tissue correlated
with shorter patient survival times (Figure 1C, L1-CAM: relative
risk 5 1.8, P 5 0.014). It is known that the majority of sporadic
ccRCC is characterized by VHL gene mutations, which leads to
a dysregulation of the function of the VHL protein (22). To analyze
if VHL mutations are involved in the upregulation of L1-CAM in
ccRCC, we investigated the expression of L1-CAM in a small TMA
consisting of 15 ccRCC (eight with WT VHL and seven with VHL
frameshift mutations). Surprisingly, six of seven VHL-mutated
ccRCC did not express L1-CAM (Figure 1D), whereas in three of
seven VHL WT ccRCC, a strong L1-CAM expression was detect-
able (Figure 1E). To confirm the specificity of the L1-CAM anti-
body (L1-14.10), we used an IgG isotype-specific antibody for our
immunohistochemical staining on human kidney tissue (Figure 1F)
and transfected L1-CAM-specific siRNA in A498 VHL cells to
perform L1-CAM (antibody L1-14.10)-specific western blot analysis
(Figure 1G).
L1-CAM expression is downregulated in VHL-deficient renal cancer
cells
To investigate if the VHL protein is involved in the regulation of
L1-CAM, we analyzed the L1-CAM expression in two VHL
negative cell lines (A498 neo, 786-0 neo) and their WT VHL-
expressing counterparts (A498 VHL and 786-0 VHL). Interestingly,
we found in VHL-deficient cells significantly lower levels of L1-
CAM protein compared with their WT counterparts (Figure 2A). With
immunofluorescence analysis (Figure 2B) and western blot analysis of
Fig. 2. L1-CAM expression is downregulated in VHL-deficient renal cancer cells. (A) Western blot analysis with VHL, Hemagglutinin antibody or L1-CAM-
specific antibodies in lysates of A498 and 786 cells stable transfected with empty (neo) or Hemagglutinin-tagged VHL vector. Equal loading of protein samples
were determined with b-actin-specific antibodies. (B) Immunofluorescence analysis of L1-CAM expression in A498 and 786-0 cells. A498 and 786-0 were
incubated with an L1-CAM-specific antibody followed Alexa 488-coupled (green) secondary antibody. Scale bars represent 50 lm. (C) Membrane fractions from
A498 and 786-0 cells were analyzed by western blot with L1-CAM-specific antibody. b-Actin was used to show equal protein loading. (D) mRNA was isolated
from A498 and 786-0 cells and reverse transcription–PCR was performed with L1-CAM-specific primers. b-Actin was used as an internal control. (E) Real-time
PCR results with L1-CAM-specific primers are depicted in a graph. The 786-0 VHL cells showed a 27.4-fold induction of L1-CAM mRNA compared with 786-
0 neo cells. P , 0.01 considered statistically significant compared with 786-0 neo cells. (F) A498 VHL cells were treated for 3, 24 and 48 h under normoxic or
hypoxic (1% O2) conditions. Cell lysates were analyzed by L1-CAM-specific western blot. b-Actin was used to show equal protein loading. (G) A498 VHL cells
were left untreated or treated for 24 h with 200 lM cobalt chloride (CoCl2) and lysates were prepared and investigated by western blot analysis using L1-CAM or
hypoxia inducible factor (HIF)-2a specific antibodies. b-Actin was used to determine equal protein loading.
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isolated cell membranes (Figure 2C), we were able to confirm this
data. Next, we isolated mRNA from the renal carcinoma cells and
performed reverse transcription–PCR experiments. As shown in
Figure 2D, only 786-0 VHL cells demonstrated higher levels of L1-
CAM mRNA compared with its VHL-deficient counterpart. In con-
trast to 786-0 cells, L1-CAM mRNA levels in A498 neo and A498
VHL cells were not different (Figure 2D). These results were con-
firmed by real-time PCR (Figure 2E). To investigate if L1-CAM
downregulation in VHL mutant renal cancer cells is hypoxia inducible
factor dependent, we incubated the cells under hypoxic conditions.
Importantly, hypoxia did not lead to a significant downregulation of
L1-CAM protein expression in A498 VHL cells (Figure 2F). Similar
results were obtained in 786-0 VHL cells (data not shown) and were
confirmed by the treatment with the hypoxia mimicking reagent
cobalt chloride (Figure 2G).
L1-CAM expression is involved in the chemoresistance of renal cancer
cells against cisplatin
To determine the role of L1-CAM in renal cancer cell survival, we
treated renal cancer cells with the chemotherapeutic agent cisplatin in
the presence or absence of L1-CAM-specific siRNA. Interestingly, the
knockdown of L1-CAM in 786-0 VHL cells alone increased the num-
ber of apoptotic cells (Figure 3A). Although 90% of the 786-0 VHL
cells were resistant against 10 lg cisplatin treatment, the knockdown
of L1-CAM led to a strong induction of apoptosis (7-fold) after 10 lg
cisplatin treatment. In contrast to 786-0 VHL cells, the knockdown of
L1-CAM alone did not induce apoptosis in A498 VHL (Figure 3B)
and Fo¨hn cells (Figure 3C), but both cell lines exhibited a significant
induction of apoptosis after the treatment with 10 lg cisplatin (Figure 3B
and C). The successful downregulation of L1-CAM by siRNA is
depicted in each graph of Figure 3. In addition, we investigated if
Fig. 3. Knockdown of L1-CAM in renal cancer cells increases cell death after cisplatin treatment (CDDP). 786-0 VHL (A), A498 VHL (B), Fo¨hn cells (C) or
A498 VHL cells (D) were transfected with scrambled (sc-siRNA) or L1-CAM-specfic siRNA (L1-siRNA). Forty-eight hours after transfection, cells were left
untreated () or treated for 24 h with 1 or 10 lg cisplatin (CDDP), sunitinib (5 lM) or rapamycin (20 ng/ml) and cell cycle analysis were performed. Graph
represents the percentage of cells in subG1/G0 phase (apoptotic cells), after the treatment with CDDP.
P, 0.05 considered statistically significant compared with
sc-siRNA-transfected cells treated with cisplatin (sc-siRNA þ CDDP), P , 0.01 considered statistically significant compared with sc-siRNA-transfected cells
(sc-siRNA). To demonstrate successful knockdown of L1-CAM, western blots of lysates from sc-siRNA- and L1-siRNA-transfected cells are included in the
graphs. Membranes were reprobed with b-actin-specific antibodies to confirm equal protein loading. n.s., not significant. (E) Forty-eight hours after siRNA
transfection, the proliferation of A498 VHL cells was measured using an MTT proliferation assay as described under Materials and Methods. P , 0.001
considered statistically significant compared with sc-siRNA-transfected A498 VHL cells. (F) Seventy-two hours after siRNA transfection, A498 VHL cells were
lysed and western blot analysis were performed with L1-CAM or cyclin D1-specific antibodies. b-Actin was used to demonstrate equal protein loading.
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the L1-CAM expression in renal cancer cells mediates also resistance
against the clinically used reagents sunitinib and rapamycin. As
shown in Figure 3D, the downregulation of L1-CAM in A498 VHL
cells induced the cytotoxic effects of sunitinib and rapamycin, dem-
onstrating that L1-CAM expression in renal cancer cells is involved in
the resistance against clinically used therapeutic reagents.
Although the downregulation of L1-CAM did not induce apoptosis
in A498 cells, we present evidence that L1-CAM is involved in the
proliferation of renal cancer cells (Figure 3E). Furthermore, L1-CAM
downregulation decreased the cyclin D1 expression in renal cancer
cells (Figure 3F).
The transcription factor PAX8 is regulated by the VHL protein
It is known that the transcription factor PAX6 can regulate L1-CAM
expression in the developing brain (23). PAX6 is not expressed in the
kidney, but PAX2 and PAX8 are known to play important roles in the
development of the kidney (24). To determine the mRNA expression
levels of PAX8 in VHL WT and VHL-mutated renal cancer cells, we
performed reverse transcription–PCR experiments. Interestingly, the
splice variant PAX8A was downregulated in A498 and 786-0 neo cells
(Figure 4A). In addition, in 786-0 neo cells, we observed also a strong
reduction of the PAX8B splice variant. By real-time PCR, we were
able to confirm that VHL WT RCC cells expressed significant higher
Fig. 4. Increased PAX8 levels in VHL expressing renal cancer cells. (A) Reverse transcription–PCR results with PAX8-specific primers in A498 neo, A498 VHL,
786 neo and 786 VHL cells. Arrows indicate the four different splice variants of PAX8 (A–D). (B) Real-time PCR data represent a 2.9-fold (A498 VHL) and a 3.8-
fold (786-0 VHL) induction of PAX8 mRNA compared with the VHL-deficient A498 neo and 786-0 neo cells, respectively. P , 0.05 considered statistically
significant compared with A498 neo cells. P , 0.01 considered statistically significant compared with 786-0 neo cells. (C) Western blot analysis of nuclear
extracts of A498 neo, A498 VHL, 786-0 neo and 786-0 VHL cells with PAX8-specific antibodies. Membranes were reprobed with Histone deacetylase-1
antibodies to demonstrate equal sample loading. (D) Densitometric analysis of nuclear PAX8 protein expression shown in 3C. P , 0.05 considered statistically
significant compared with A498 neo cells. P , 0.01 considered statistically significant compared with 786-0 neo cells.
Fig. 5. L1-CAM and PAX8 are co-expressed in collecting ducts cells of normal renal tissue. Immunohistochemistry was performed on serial sections of normal
renal tissue using PAX8-specific (A) and L1-CAM-specific (B) antibodies. Scale bars represent 50 lm. (C) Double immunofluorescense staining of PAX8 (red)
and L1-CAM (green) expressing tubular cells in normal renal tissue. White arrows indicate PAX8-expressing cells, which do not express L1-CAM. Scale bars
represent 20 lm.
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levels of PAX8 mRNA than the VHL-deficient counterparts (Figure 4B).
In addition, we confirmed with isolated nuclear proteins that VHL-
deficient A498 and 786-0 cells expressed lower PAX8 protein levels
compared with the VHL WT-expressing cells (Figure 4C). In
Figure 4D, densitometric analysis of Figure 4C is shown.
The transcription factor PAX8 and L1-CAM colocalize in collecting
duct cells of human kidney
To examine the localization of PAX8 and L1-CAM in the human
kidney, we performed immunohistochemistry analysis on serial sec-
tions of normal renal tissue. Strong PAX8 expression (Figure 5A) was
observed in nuclei of L1-CAM-expressing collecting duct cells
(Figure 5B). These data were confirmed by immunofluorescence anal-
ysis (Figure 5C). In contrast to the immunohistochemistry data, we
also found PAX8-positive tubular cells that did not express L1-CAM
(Figure 5C white arrows).
PAX8 expression in renal tumor samples
The expression of PAX8 in renal cancer tissue was analyzed immuno-
histochemically in our TMA with 282 renal cancer samples. Represen-
tative stainings for the PAX8 expression in normal kidney and
tumor samples (negative, weak and strong expression) are shown
in Figure 6A. The obtained results are summarized in a diagram
(Figure 6B). Only 34.7% of the analyzed renal cancer samples expressed
Fig. 6. Expression of PAX8 in normal renal tissue and renal cancer tissue and PAX8 knockdown increases L1-CAM expression. (A) Immunohistochemistry
images showing the expression of PAX8 in normal kidney and a representive image of negative, weak positive and strong positive L1-CAM staining in renal cancer
patients (RCC). Scale bars represent 50 lm. (B) Pie charts demonstrate the percentage of negative (blue), weak positive (yellow), moderate positive (red) and
strong PAX8-positive (maroon) cases of RCC. (C) Serial sections of a TMA with 31 ccRCC patients were investigated by immunohistochemical analysis. Results
were divided in four groups representing group 1: PAX8-negative and L1-CAM-negative patients, (white bar) group 2: PAX8-positive and L1-CAM-negative
patients (light gray bar), group 3: PAX8-negative and L1-CAM-positive patients (gray bar) and group 4: PAX8-positive and L1-CAM-positive patients (black bar).
Numbers in the bars are belonging to the respective group. Representive immunohistochemical images of each group are shown on the right side of the figure. (D)
Forty-eight hours after sc-siRNA or PAX8-siRNA transfection, the migration of A498 neo cells were analyzed in Boyden chamber assay. P, 0.001 considered
statistically significant compared with sc-siRNA-transfected A498 neo cells. (E) Seventy-two hours after the transfection with siRNA, lysates of A498 neo cells
were analyzed by western blot with PAX8-specific antibodies. Equal sample loading was controlled by b-actin-specific antibodies. (F) A498 neo and (G) Fo¨hn
cells were transfected with control (sc-siRNA) or PAX8 (PAX8-siRNA). Seventy-two hours after transfection, cell lysates were investigated by western blot
analysis with PAX8- or L1-CAM-specific antibodies. To confirm equal protein loading membranes were incubated with b-actin antibodies. (H) ChIP assay was
performed in A498 VHL cells as described under Materials and Methods to demonstrate PAX8 protein binding to the L1-CAM promoter.
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PAX8. The highest levels of PAX8 expression were detectable in papil-
lary carcinomas, most of which (71.4%) were positive for PAX8. In clear
cell carcinomas, the rate of PAX8 positivity was 29.1% and none of the
chromophobe RCC (0/10) was positive for PAX8. In addition, we
performed on serial sections of a TMA with 31 different ccRCC patients
immunhistochemical analysis with L1-CAM- and PAX8-specific
antibodies. Interestingly, 50% of ccRCC patients, which were negative
for PAX8, showed induced L1-CAM expression (Figure 6C).
To evaluate the role of PAX8 in renal cancer cell migration, we
downregulated PAX8 protein expression by specific PAX8 siRNA and
performed a transwell migration assay. Interestingly, the knockdown
of PAX8 increased the migration of A498 (Figure 6D). The successful
knockdown of PAX8 is shown in Figure 6E. To investigate if PAX8
can regulate L1-CAM expression in RCC, we downregulated PAX8
protein expression by siRNA in A498 neo cells and Fo¨hn cells. The
downregulation of PAX8 led to a significant increase of L1-CAM
protein levels in A498 (Figure 6F) and Fo¨hn cells (Figure 6G). Similar
results were obtained in 786-0 VHL and A498 VHL cells (data not
shown). In addition, by ChIP analysis, we could show that PAX8 is
able to bind to the L1-CAM promoter (Figure 6H).
Discussion
L1-CAM overexpression has been found in several tumors like mel-
anoma, ovarian and colon cancer (25). In addition, the study of Meli
et al. (26) described L1-CAM expression in renal cancer tissue. In
ccRCC, conflicting data exist about the expression and role of L1-
CAM in renal cancer progression. Although it has been reported that
L1-CAM was expressed in 47% of ccRCC and L1-CAM expression
correlated with metastasis (7), another study did not find L1-CAM
expression in ccRCC specimens (8). Therefore, we reinvestigated the
expression of L1-CAM in 282 RCC patients by immunohistochemical
analysis. Notably, we used the same antibody for our investigations as
the second study (8). In contrast to the data from Huszar et al. (8), we
detected in 49% of ccRCC patients L1-CAM expression and more
important L1-CAM expression correlated with shorter patients sur-
vival. In this context, it has been reported that L1-CAM expression
correlated with poor prognosis and metastasis in ovarian cancer (27).
In addition, a recent publication described L1-CAM as a novel in-
dependent prognostic factor in extrahepatic cholangiocarcinomas as-
sociated with poor patient survival (28). Furthermore, our study
demonstrated that targeting L1-CAM in ccRCC may represent
a new therapeutic option to overcome the resistance of renal cancer
cells against therapeutic agents like cisplatin, sunitinib and rapamy-
cin. In this line, it has been shown that L1-CAM expression confers
chemoresistance in melanoma (16), pancreatic adenocarcinoma (29)
and ovarian carcinoma cell lines (30). Importantly, patients with low
L1-CAM expressing ovarian tumors exhibited a better response to
chemotherapy and had a statistically longer progression-free survival
(31), highlighting the potential therapeutic usefulness of L1-CAM as
a target molecule in the treatment of ovarian cancer patients.
In normal tissue, L1-CAM expression is only found in peripheral
nerve bundles and renal tubules, but increased L1-CAM levels are
often found in various cancers (8). Therefore, it is crucially important
to identify factors, which can regulate L1-CAM in cancer cells.
Interestingly, in biopsies of VHL-mutated ccRCC patients and VHL-
deficient cell lines L1-CAM was downregulated. In addition, we dem-
onstrated that re-expression of VHL in VHL-deficient renal cancer
cells increased the expression of L1-CAM in a hypoxia inducible
factor-independent manner. The tumor suppressor gene VHL is inac-
tivated in .80% of sporadic RCC (32) and re-expression of VHL in
renal cancer cells prevents the tumorigenic effects in severe combined
immunodeficient mice (32–35). In contrast to the tumor suppressor
function of VHL in the kidney, a recent study has demonstrated that
the expression of VHL WT together with low Carbonic Anhydrase IX
expression was associated to a particular aggressive ccRCC pheno-
type (36). In addition, VHL WT together with high Vascular Endo-
thelial Growth Factor expression was associated with tumor
aggressiveness and poor survival of renal cancer patients (37). There-
fore, our data suggest that VHL-induced L1-CAM expression and L1-
CAM expression in ccRCC correlated with poor patients prognosis are
in line with the above described studies (36,37).
In colon cancer, it has been shown that the b-catenin-T cell tran-
scription factor transcriptional complex activates the L1-CAM gene
(38). We could not identify b-catenin as a regulator of L1-CAM
expression in RCC (data not shown). In contrast, we present evidence
that PAX8 is involved in the regulation of L1-CAM. With CHIP
analysis, we present evidence that PAX8 is able to bind to the L1-
CAM promoter and the downregulation of PAX8 induced the expres-
sion of L1-CAM in VHL negative and WT renal cancer cells. Impor-
tantly, in a big fraction of ccRCC patients, PAX8 downregulation was
accompanied with increased L1-CAM expression, assuming that
PAX8 is a negative regulator of L1-CAM in renal cancer cells. Re-
cently, an immunohistochemical study has characterized the expres-
sion of PAX8 in normal kidney and renal tumors (39). The expression
of PAX8 in papillary RCC is basically in line with the study of Tong
et al. (39), who also found the highest PAX8 levels in papillary RCC.
However, we could not confirm the rather high rate of PAX8 positivity
in our cohort of ccRCC. This might be due to methodological differ-
ences or could be explained by the existence of four PAX8 mRNA
isoforms, which have been identified in human kidney cell lines (40).
Interestingly, our data demonstrate that the downregulation of PAX8
increased the migration of renal cancer cells. This induction might be
explained by an increase in L1-CAM expression as L1-CAM expres-
sion in normal and cancer cells is involved in enhanced cell motility
(38). PAX8 and PAX2 are important developmental transcription fac-
tors in renal organogenesis (11,41,42) and are often co-expressed
during development. In the developing nephric duct in mice, both
PAX2 and PAX8 are required for specifying the nephric lineage
(11). However, although PAX2 and PAX8 are expressed together in
bladder and ovarian cancer cell lines, RNA interference against just
the PAX2 gene leads to cell death (43). Therefore, a greater under-
standing of the coordinate interplay between different PAX proteins in
development and cancer is required.
In summary, our data demonstrated that L1-CAM expression in
ccRCC is associated with a poor prognosis and represents an attractive
therapeutic target molecule for the treatment of ccRCC patients.
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